RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for inflammatory and immunological diseases and cancer. The company’s work centers on drug candidates intended for use in areas such as immunology, inflammation, and oncology, with development activities conducted through its corporate research and clinical organization in the United States.
Tilikausi 2024 · muutos edellisvuodesta
Kehitys 2019–2024
Liiketoiminta
Osuus liikevaihdostaDrug discovery and development efforts targeting inflammatory and immune-mediated diseases.
Therapeutic candidates and research programs aimed at cancer indications.
Early-stage discovery, screening, and translational work supporting the pipeline.
Asiakkaat
RAPT does not currently sell commercial products; its near-term counterparties are primarily clinical investigators, contract research organizations, manufacturers, regulators, and potential development partners. If any candidate is approved, the end customers would be physicians, hospitals, and payors that influence adoption and reimbursement in the U.S. healthcare system.
CROs, trial sites, and manufacturers that support testing and supply of drug candidates.
Biopharma companies that may license, co-develop, or commercialize candidates.
Physicians and hospitals that would prescribe or administer approved therapies.
Insurers and government payors that determine coverage and reimbursement.
Strategia
RAPT’s strategy is to advance its pipeline through preclinical and clinical development, using external partners where needed for research, manufacturing, and trial execution. The company also emphasizes maintaining intellectual property protection and preserving optionality for future financing, collaborations, or licensing transactions that could support development and eventual commercialization.
Clinical and preclinical progress is the main value driver for a therapeutics company with no product revenue.
The company lacks internal sales and distribution capabilities and may need third parties to bring products to market.
Ongoing R&D and clinical work require external capital until product revenue exists, if ever.
Maantiede
RAPT is headquartered and operates in the United States, where its research, clinical development, and corporate functions are centered. Its business is also exposed to global clinical-trial, manufacturing, and regulatory dependencies, since trials, suppliers, and future commercialization could involve non-U.S. counterparties and jurisdictions.
Riskit
RAPT faces the typical risks of a clinical-stage biotech company: pipeline failure, long development timelines, regulatory uncertainty, and dependence on external funding. Its future commercial success also depends on reimbursement, intellectual property protection, supply chain reliability, and the ability to build or outsource sales and distribution capabilities if a product is approved.
- Clinical development failure or delayVaikutus: KorkeaTodennäköisyys: Korkea
Drug candidates may not show sufficient safety or efficacy, or trials may take longer than planned.
Kohdistuu - Funding and liquidity dependenceVaikutus: KorkeaTodennäköisyys: Korkea
The company expects to need substantial additional capital before generating product revenue.
Kohdistuu - Supply chain and regulatory disruptionVaikutus: KeskitasoTodennäköisyys: Korkea
Clinical trials depend on CROs, manufacturers, and FDA/regulatory operations.
Kohdistuu - Commercialization capability gapVaikutus: KeskitasoTodennäköisyys: Kohtalainen
RAPT currently has no sales, marketing, or distribution infrastructure.
Kohdistuu: Future approved products
- Competition and IP riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Larger, better funded biotech and pharma companies may develop superior or earlier therapies.
Kohdistuu - Reimbursement and pricing pressureVaikutus: KeskitasoTodennäköisyys: Matala
Payors may restrict coverage, require discounts, or demand additional evidence.
Kohdistuu: U.S. pharmaceutical commercialization
Kirjanpito
Harkinnanvaraiset erätExternal trial, lab, and manufacturing costs are expensed as incurred, affecting quarterly comparability.
Vaikutus: Reported operating loss
Cash is invested in money market funds, corporate debt, commercial paper, and agency securities.
Vaikutus: Other income, net
Non-refundable advance payments are recognized as expense when goods or services are received.
Vaikutus: Timing of operating expenses
Any partnering deal could require judgment on performance obligations and revenue timing.
Vaikutus: Potential future revenue recognition
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Rapport Therapeutics, Inc.
RAPP · Pharmaceutical Preparations
Replimune Group, Inc.
REPL · Biological Products, (No Diagnostic Substances)
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
Indaptus Therapeutics, Inc.
INDP · Pharmaceutical Preparations
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
Päivitetty: 24.9.2026